LFX453

LFX453 is a topically administered investigational drug developed by Novartis for the treatment of actinic keratosis and external genital warts. It was formulated as a cream and evaluated in clinical trials to determine its safety, tolerability, pharmacokinetics, and efficacy. The mechanism of action for LFX453 remains undefined in public sources; however, it was studied alongside imiquimod (a known TLR7 agonist), suggesting it may have been hypothesized to modulate immune responses in the skin. Clinical development reached phase 2 for both actinic keratosis and genital warts but was discontinued after failing to demonstrate sufficient efficacy over placebo or comparator treatments[1][3][4][5]. The drug showed minimal systemic absorption when applied topically[2].